Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidural Resiniferatoxin for Intractable Cancer Pain
NCT03226574Phase 1Completed
- Sponsor
- Sorrento Therapeutics
- Start
- Sep 2017
- Primary completion
- Mar 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of resiniferatoxin in cancer pain, sponsored by Sorrento Therapeutics. Primary endpoints: Dose Limiting Toxicity at 3 months and Maximum Tolerated Dose at 3 months. Started Sep 2017; status: completed.
02
Drugs
resiniferatoxin
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT03226574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226574.